LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3051% below fair value
$3.82−0.31 (-7.51%)
Close on Nov 16, 2026Market cap $120.03MP/E –Yield –
LENZ Therapeutics cash
Cash and short-term investments held at the end of each period.
LENZ Therapeutics's cash was $220.00M at Jun 30, 2026. For fiscal 2025 it was $292.30M, up 39.8% from the year before. The highest annual figure on record is $376.98M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $292.30M | +39.8% |
| FY2024 | Dec 31, 2024 | $209.10M | +13.5% |
| FY2023 | Dec 31, 2023 | $184.30M | -35.0% |
| FY2022 | Dec 31, 2022 | $283.60M | -24.8% |
| FY2021 | Dec 31, 2021 | $376.98M | +1805.7% |
| FY2020 | Dec 31, 2020 | $19.78M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $220.00M | +5.0% |
| Q1 FY2026 | Mar 31, 2026 | $258.40M | +33.1% |
| Q4 FY2025 | Dec 31, 2025 | $292.30M | +39.8% |
| Q3 FY2025 | Sep 30, 2025 | $202.20M | -6.9% |
| Q2 FY2025 | Jun 30, 2025 | $209.60M | +6.9% |
| Q1 FY2025 | Mar 31, 2025 | $194.10M | -9.0% |
| Q4 FY2024 | Dec 31, 2024 | $209.10M | +13.5% |
| Q3 FY2024 | Sep 30, 2024 | $217.20M | -7.2% |
| Q2 FY2024 | Jun 30, 2024 | $196.10M | -20.5% |
| Q1 FY2024 | Mar 31, 2024 | $213.30M | +80764761.8% |
| Q4 FY2023 | Dec 31, 2023 | $184.30M | -35.0% |
| Q3 FY2023 | Sep 30, 2023 | $234.00M | -23.3% |
| Q2 FY2023 | Jun 30, 2023 | $246.70M | -24.9% |
| Q1 FY2023 | Mar 31, 2023 | $264 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $283.60M | -24.8% |
| Q3 FY2022 | Sep 30, 2022 | $305.10M | -22.7% |
| Q2 FY2022 | Jun 30, 2022 | $328.30M | -14.0% |
| Q1 FY2022 | Mar 31, 2022 | $352.10M | +98.9% |
| Q4 FY2021 | Dec 31, 2021 | $376.98M | +1805.7% |
| Q3 FY2021 | Sep 30, 2021 | $394.80M | +3644.3% |
| Q2 FY2021 | Jun 30, 2021 | $381.97M | +2701.8% |
| Q1 FY2021 | Mar 31, 2021 | $177.02M | – |
| Q4 FY2020 | Dec 31, 2020 | $19.78M | – |
| Q3 FY2020 | Sep 30, 2020 | $10.54M | – |
| Q2 FY2020 | Jun 30, 2020 | $13.63M | – |
See a number that looks wrong?